Volume 17 Supplement 2
33rd International Symposium on Intensive Care and Emergency Medicine
In vitro efficiency of Amikacin Inhale, a novel drug-device delivery system
© Kadrichu et al.; licensee BioMed Central Ltd. 2013
Published: 19 March 2013
An estimated lung dose (ELD) for On-vent setting was measured in vitro after collecting aerosolized amikacin from a filter at the end of an endotracheal tube during ventilation. The ELD for the HH device was calculated from the fine particle fraction (FPF <5 µm) post-mouthpiece, multiplied by the in vitro delivered dose post-mouthpiece. FPF <5 µm reflects lung deposition observed during phase 2 clinical trials . Eighty-one nebulizers with volume median diameter (VMD) of 4.4 ± 0.5 µm and output rates of 0.23 ± 0.10 ml/minute were tested for each system. Delivered dose data were fit to the independent variables (that is, VMD and output rates) using a least-squares fit with 95% confidence limits.
Total percentage recoveries for On-vent and HH test runs were between 85% and 115% of the nominal dose. The mean ELDs were 50 ± 9% (On-vent) and 49 ± 11% (HH) of the nominal dose. Nebulizers with longer dosing times and lower VMDs had higher ELD values for both delivery systems.
The results support the use of the PDDS Clinical with either system to administer aerosolized amikacin with high efficiency and no dose adjustment is required when switching from the On-vent to the HH system for extubated patients.
- Fink J, et al.: High in vivo amikacin lung deposition after NKTR-061 dosing correlates with in vitro aerosol characterization. Am J Respir Crit Care Med 2008, 177: A530.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.